The Gut, The Brain and Parkinson's - May 2018

There is a growing body of evidence which links Parkinson's to the gastrointestinal tract, opening potential new avenues for treatment.

Collaboration to Ensure Research Results are Shared - May 2018

23 members of the Association of Medical Research Charities (AMRC) are working in collaboration to develop and launch a joint publication platform.

Korean-based Pharma Advances Clinical Trial of SR-exenatide in Parkinson's - May 2018

Korean-based firm Peptron recently obtained an exclusive worldwide license from the National Institute on Aging (NIA), a National Institutes of Health (NIH) center, covering the delivery and use of sustained-release (SR) exenatide in the treatment of Parkinson’s and other neurodegenerative disorders.

Precision Medicine: Treating the Sub-groups of Parkinson's - April 2018

Important shifts are taking place in the minds of clinicians, researchers and patients. One potentially important development is that of precision medicine...

Stem Cell Therapies - Research Update - April 2018 

...an update from Professor Roger Barker

What is the Link between Diabetes and Parkinson's - March 2018

Parkinson’s is a complex condition with a variety of causes we don't yet fully understand, and while a small number of cases are associated with genetic mutations, the majority originate from a combination of factors. Understanding the underlying causes of PD is becoming an invaluable route in the discovery of new and promising treatments..

Trial of Repurposed Drug Nilotinib in Parkinson's is Recruiting - March 2018

This study is an example of the potential of repurposing drugs, already approved to treat other conditions, in Parkinson's. This can lead to faster approved therapies, since repurposed drugs have already been tested for safety and tolerability in Phase 1 trials in humans.

Herantis Pharma begins Recruitment for CDNF Trial - February 2018

CDNF is a novel drug candidate for the treatment of neurodegenerative diseases such as Parkinson's. It is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties and is patented internationally by Herantis.

The LRRK2 Gene and Parkinson's and the Link with Crohns Disease - January 2018

Leucine-rich repeat kinase 2 (LRRK2) is a known genetic contributor to Parkinson's disease (PD). Recently, a large genetic study of more than 24,500 people has found that Crohn’s, an inflammatory bowel condition, and genetic forms of PD share variants of the LRRK2 gene.

An Interview with Professor Patrik Brundin - January 2018

Ben Stecher interviews Professor Patrik Brundin - lead at the Center for Neurodegenerative Science at Van Andel Research Institute and co-editor of the Journal of Parkinson's Disease.

Identifying Treatments for Parkinson’s Using Patient-derived Induced Neurons - January 2018

Our research committee has approved funding for a revolutionary technique which uses a person with Parkinson's own skin cells to grow neurons affected by their particular type of this disease to then treat with certain drugs.

Small Molecule Drug Offers Neuroprotection with Promise for PD - December 2017

An international team of researchers has shown that a new small-molecule drug can restore brain function and memory in pre-clinical models of Alzheimer's disease. The drug works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envisage that this drug could also be used to treat Parkinson's.

Stem Cell Therapies - Research Update - December 2017

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Scientists are searching for ways to replace these nerve cells.

Synpromics collaboration with UCL in gene therapy for Parkinson’s - December 2017

Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system to develop a gene therapy for Parkinson’s.

'Voyager' Recruits Patients for Gene Therapy Delivery - November 2017

Voyager Therapeutics announced it is recruiting participants for the company’s new Phase 1 clinical trial to test a new approach for their gene therapy VY-AADC01 in Parkinson’s patients.

Research Update Meeting - November 2017

Nilotinib Trial Recruitment Underway - November 2017

Recruitment will open on an ongoing basis at a maximum of 25 clinical sites across the United States.

Simvastatin Trial Underway - November 2017

The cholesterol-lowering drug Simvastatin is to be trialled as a potential neuroprotective treatment for Parkinson’s.

Parkinson's and the Beta2-Adrenoreceptor Agonist in Asthma Medication - October 2017

Researchers have found that compounds in certain drugs used in the treatment of asthma, may also have beneficial effects in Parkinson’s disease.

Alpha-synuclein oligomers: a new hope - August 2017

A report part funded by The Cure Parkinson's Trust assesses the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discusses the advances in our understanding of the role of alpha-synuclein in Parkinson’s and current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.

The Association of Pesticide Use and Parkinson's - August 2017

Researchers assessed the influence of occupational pesticide use on the prevalence of Parkinson's Disease in people with information available concerning occupational, residential, and household sources of pesticide exposure.

Breaking News: Diabetes Drug Shows Potential as Disease-Modifying Therapy for Parkinson’s - August 2017

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

Reducing Inflammation in Parkinson's using a Clinically Approved Cancer Drug - August 2017

Based on the wealth of evidence that inflammation plays a key role in diseases of the central nervous system, it is thought this line of treatment using a clinically approved cancer drug has significant potential to slow or stop disease progression in Parkinson's.

FDA Approval of Nilotinib in Collaboration Trial - July 2017

The Cure Parkinson's Trust has collaborated with The Michael J Fox Foundation (MJFF) and the Van Andel Research Institute (VARI) of Grand Rapids, Michigan on the clinical development of nilotinib toward the launch of this clinical trial.

Dogs to be Taught to Sniff Out Parkinson's - July 2017

Dogs could soon be used to sniff out Parkinson’s disease years before symptoms start to show.

Abnormal Protein in Parkinson's Triggers an Immune Response - June 2017

Researchers have found the first direct evidence that autoimmunity -- in which the immune system attacks the body's own tissues -- plays a role in Parkinson's Disease.

Trazodone could be Effective in Slowing Disease Progression in Parkinsons - April 2017

New research study suggests depression treatment could show a positive effect in neurodegenerative brain conditions

'Milestones' in 200 Years of Parkinson's Research - March 2017

Marking the 200th anniversary of the first published description by James Parkinson of the disease that would come to bear his name, the Journal of Parkinson’s Disease has published a special issue that features invited commentaries by those responsible for some of the greatest advances in understanding and treating the disease.

Bowel Cancer Medication could help combat Early-Onset Parkinson's - March 2017

Folinic acid can protect neurons in laboratory models, report scientists. The study suggests that folinic acid, which is used in medications to treat bowel cancer, can also protect neurons associated with Parkinson's.

Discovery of Genetic 'Switch' Could Prevent Symptoms of PD - February 2017

A genetic 'switch' has been discovered by MRC researchers at the University of Leicester which could help to prevent or delay the symptoms of Parkinson's disease.

Acorda announces Positive Phase 3 Clinical Trial Results for the Inhalable Drug CVT-301 - February 2017

Acorda have announced positive topline data from a Phase 3 clinical trial for CVT-301, an investigational therapy studied as a treatment for OFF periods in people with Parkinson’s.

PD Breakthrough Could Come From a Single Protein - January 2017

One single protein could be the key to developing groundbreaking treatment for various neurodegenerative diseases including Parkinson’s.

A Steroid Originally Found in Dogfish Could Treat Parkinson's - January 2017

A naturally-occurring compound has been found to block a process thought to cause Parkinson’s, and target its toxic products, scientists have reported.

Diabetes Drug Slows Experimental Parkinson’s Disease Progression. - December 2016

New data published today shows this drug preserves critical brain function in laboratory models of Parkinson’s.

New Evidence Suggests Parkinson's Might Not Start in The Brain - December 2016

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.

'Gap' found in Brain's Firewall against Parkinson's - October 2016

An NIH-funded animal model study identifies a key player in the progression of Parkinson's.

Vaccine for Parkinson's Reports Positive Results from Boost Study - September 2016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson's protein alpha-synuclein.

Diabetes Drug Focus of New Clinical Trial for Parkinson’s - September 2016

A clinical trial, part of our Linked Clinical Trials programme, is now underway at Cedars-Sinai in Los Angeles to investigate the use of the diabetes drug Liraglutide to slow or stop the progression of Parkinson's.

CPT Collaborates to Assess the Clinical Use of Nilotinib in Parkinson's - July 2016

The Michael J. Fox Foundation, Van Andel Research Institute and The Cure Parkinson’s Trust today announced plans to collaborate on the clinical development of nilotinib in preliminary studies as a treatment for Parkinson’s.

European Commission approves ONGENTYS® (opicapone)

BIAL announced today that its product ONGENTYS® (opicapone) for Parkinsons was approved by the European Commission. BIAL will make ONGENTYS® available for people with Parkinson’s across Europe in 2016 and 2017.

Blocking a Key Enzyme Stops Parkinson's Symptoms in Animal Model

Researchers at Johns Hopkins say they have gleaned two important new clues in the fight against Parkinson's: that blocking an enzyme called c-Abl prevents the disease in an animal model and that a chemical tag on a second protein may signal the disorder's presence and progression.

Researchers Open New Path of Discovery in Parkinson's Disease

Two genes associated with Parkinson's disease are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease, a new study indicates.

Parkinson's Cell Transplants Show Good Reinnervation After 24 Years

A postmortem examination of a patient with Parkinson's who underwent dopaminergic cell transplantation 24 years ago has shown that the transplanted neurons had reinnervated the brain for all that time.

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?

A research paper recently published in the Journal of Parkinson's Disease discusses an impending clinical trial in Parkinson's disease (PD) using parthenogenetic stem cells for transplantation into PD patients.

World First Blood Test for Parkinson's

Researchers at La Trobe University Melbourne, Australia have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.

Our Research Update Meeting April 2016

At our recent research update meeting in April, Prof Roger Barker, Dr Mariah Lelos and CPT's Dr Richard Wyse presented their research news to a packed audience of Parkinson's advocates...